Search Results - "SCHAPIRO, Jonathan M"

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis by Cutrell, Amy G., Schapiro, Jonathan M., Perno, Carlo F., Kuritzkes, Daniel R., Quercia, Romina, Patel, Parul, Polli, Joseph W., Dorey, David, Wang, Yongwei, Wu, Sterling, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L., Baker, Mark, Talarico, Christine L., Clair, Marty St, Jeffrey, Jerry, White, C. Thomas, Vanveggel, Simon, Vandermeulen, Kati, Margolis, David A., Aboud, Michael, Spreen, William R., van Lunzen, Jan

“…Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3…”
Get full text

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update by Bennett, Diane E, Camacho, Ricardo J, Otelea, Dan, Kuritzkes, Daniel R, Fleury, Hervé, Kiuchi, Mark, Heneine, Walid, Kantor, Rami, Jordan, Michael R, Schapiro, Jonathan M, Vandamme, Anne-Mieke, Sandstrom, Paul, Boucher, Charles A B, van de Vijver, David, Rhee, Soo-Yon, Liu, Tommy F, Pillay, Deenan, Shafer, Robert W

“…Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success…”
Get full text

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance by Rhee, Soo-Yon, Schapiro, Jonathan M, Saladini, Francesco, Zazzi, Maurizio, Khoo, Saye, Shafer, Robert W

“…Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has…”
Get full text

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection by Seden, Kay, Gibbons, Sara, Marzolini, Catia, Schapiro, Jonathan M, Burger, David M, Back, David J, Khoo, Saye H

“…In all settings, there are challenges associated with safely treating patients with multimorbidity and polypharmacy. The need to characterise, understand and…”
Get full text

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel by Hirsch, Martin S., Günthard, Huldrych F., Schapiro, Jonathan M., Vézinet, Françoise Brun, Clotet, Bonaventura, Hammer, Scott M., Johnson, Victoria A., Kuritzkes, Daniel R., Mellors, John W., Pillay, Deenan, Yeni, Patrick G., Jacobsen, Donna M., Richman, Douglas D.

“…Resistance to antiretroviral drugs remains an important limitation to successful human immunodeficiency virus type 1 (HIV-1) therapy. Resistance testing can…”
Get full text

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance by SHAFER, Robert W, RHEE, Soo-Yon, PILLAY, Deenan, MILLER, Veronica, SANDSTROM, Paul, SCHAPIRO, Jonathan M, KURITZKES, Daniel R, BENNETT, Diane

“…Monitoring regional levels of transmitted HIV-1 resistance informs treatment guidelines and provides feedback on the success of HIV-1 prevention efforts…”
Get full text

Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1–Infected Patients with Virological Failure by Llibre, Josep M., Schapiro, Jonathan M., Clotet, Bonaventura

“…Virological suppression rates achieved with the new antiretroviral drugs in patients with virological failure and resistance to multiple drug classes are…”
Get full text

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation by Paredes, Roger, Tzou, Philip L, van Zyl, Gert, Barrow, Geoff, Camacho, Ricardo, Carmona, Sergio, Grant, Philip M, Gupta, Ravindra K, Hamers, Raph L, Harrigan, P Richard, Jordan, Michael R, Kantor, Rami, Katzenstein, David A, Kuritzkes, Daniel R, Maldarelli, Frank, Otelea, Dan, Wallis, Carole L, Schapiro, Jonathan M, Shafer, Robert W

“…HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment…”
Get full text

Dynamics of Human Immunodeficiency Virus Type 1 A6 Variant Transmissions Between Poland and Ukraine by Schapiro, Jonathan M

Get full text

Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir by BAXTER, John D, SCHAPIRO, Jonathan M, BOUCHER, Charles A. B, KOHLBRENNER, Veronika M, HALL, David B, SCHERER, Joseph R, MAYERS, Douglas L

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment by Maor, Yaakov, Schapiro, Jonathan M, Bashari, Dalia, Martinowitz, Uri

“…AbstractBackground/Purpose. Hepatitis C (HCV) is a major cause of morbidity and mortality in haemophilia patients who received clotting factor concentrates…”
Get full text

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration by Rhee, Soo-Yon, Varghese, Vici, Holmes, Susan P., Van Zyl, Gert U., Steegen, Kim, Boyd, Mark A., Cooper, David A., Nsanzimana, Sabin, Saravanan, Shanmugam, Charpentier, Charlotte, de Oliveira, Tulio, Etiebet, Mary-Ann A., Garcia, Federico, Goedhals, Dominique, Gomes, Perpetua, Günthard, Huldrych F., Hamers, Raph L., Hoffmann, Christopher J, Hunt, Gillian, Jiamsakul, Awachana, Kaleebu, Pontiano, Kanki, Phyllis, Kantor, Rami, Kerschberger, Bernhard, Marconi, Vincent C., D'amour Ndahimana, Jean, Ndembi, Nicaise, Ngo-Giang-Huong, Nicole, Rokx, Casper, Santoro, Maria M., Schapiro, Jonathan M., Schmidt, Daniel, Seu, Lillian, Sigaloff, Kim C.E., Sirivichayakul, Sunee, Skhosana, Lindiwe, Sunpath, Henry, Tang, Michele, Yang, Chunfu, Carmona, Sergio, Gupta, Ravindra K., Shafer, Robert W.

“…Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on…”
Get full text

Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes by Grossman, Zehava, Schapiro, Jonathan M, Levy, Itzchak, Elbirt, Daniel, Chowers, Michal, Riesenberg, Klaris, Olstein-Pops, Karen, Shahar, Eduardo, Istomin, Valery, Asher, Ilan, Gottessman, Bat-Sheva, Shemer, Yonat, Elinav, Hila, Hassoun, Gamal, Rosenberg, Shira, Averbuch, Diana, Machleb-Guri, Keren, Kra-Oz, Zipi, Radian-Sade, Sara, Rudich, Hagit, Ram, Daniela, Maayan, Shlomo, Agmon-Levin, Nancy, Sthoeger, Zev

“…Analysis of potentially different impact of Lopinavir/Ritonavir (LPV/r) on non-B subtypes is confounded by dissimilarities in the conditions existing in…”
Get full text

HIV-1 Protease and Reverse-Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance by Rhee, Soo-Yon, Fessel, W. Jeffrey, Zolopa, Andrew R., Hurley, Leo, Liu, Tommy, Taylor, Jonathan, Nguyen, Dong Phuong, Slome, Sally, Klein, Daniel, Horberg, Michael, Flamm, Jason, Follansbee, Stephen, Schapiro, Jonathan M., Shafer, Robert W.

“…BackgroundIt is important, for drug-resistance surveillance, to identify human immunodeficiency virus type 1 (HIV-1) strains that have undergone antiretroviral…”
Get full text

Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir by GROSSMAN, Zehava, PAXINOS, Ellen E, RAM, Daniela, PETROPOULOS, Chris J, SCHAPIRO, Jonathan M, AVERBUCH, Diana, MAAYAN, Shlomo, PARKIN, Neil T, ENGELHARD, Dan, LORBER, Margalit, ISTOMIN, Valery, SHAKED, Yael, MENDELSON, Ella

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance by Tzou, Philip L, Rhee, Soo-Yon, Descamps, Diane, Clutter, Dana S, Hare, Bradley, Mor, Orna, Grude, Maxime, Parkin, Neil, Jordan, Michael R, Bertagnolio, Silvia, Schapiro, Jonathan M, Harrigan, P Richard, Geretti, Anna Maria, Marcelin, Anne-Geneviève, Shafer, Robert W

“…Abstract Background Integrase strand transfer inhibitors (INSTIs) are expected to be widely adopted globally, requiring surveillance of resistance emergence…”
Get full text

In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1 by DANDACHE, Serge, SEVIGNY, Guy, YELLE, Jocelyn, STRANIX, Brent R, PARKIN, Neil, SCHAPIRO, Jonathan M, WAINBERG, Mark A, WU, Jinzi J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV? by Levy‐Mendelovich, Sarina, Walsh, Christopher E., Schapiro, Jonathan M., Soffer, Shelly, Klang, Eyal, Kenet, Gili

“…Introduction In the past HIV infection was a common complication of haemophilia therapy. Gene therapy trials in Haemophilia patients using rAAV have shown…”
Get full text

HIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible for Discordances Between Genotypic Drug Resistance Interpretation Algorithms by Ravela, Jaideep, Betts, Bradley J, Brun-Vézinet, Francoise, Vandamme, Anne-Mieke, Descamps, Diane, Van Laethem, Kristel, Smith, Kate, Schapiro, Jonathan M, Winslow, Dean L, Reid, Caroline, Shafer, Robert W

“…Several rules-based algorithms have been developed to interpret results of HIV-1 genotypic resistance tests. To assess the concordance of these algorithms and…”
Get full text

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART by Shafer, Robert W, Schapiro, Jonathan M

“…More than 200 mutations are associated with antiretroviral resistance to drugs belonging to six licensed antiretroviral classes. More than 50 reverse…”
Get full text